Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876280 | 0.92 | PDE1A (0.37) | MAT2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25876042 | 0.91 | MAT2A (0.33) | MAT2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25875946 | 0.90 | MAT2A (0.40) | MAT2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25876233 | 0.89 | MAT2A (0.33) | MAT2APDE2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25876309 | 0.89 | PIK3CA (0.36) | MAT2APDE2A | |
| SCHEMBL25876083 | 0.88 | MERTK (0.35) | MAT2A | |
| SCHEMBL25875917 | 0.87 | PDE2A (0.40) | PDE2AKMT2ASMN1; SMN2 | |
| SCHEMBL25876132 | 0.84 | PIK3CA (0.34) | — | |
| SCHEMBL25875905 | 0.83 | KLKB1 (0.31) | — | |
| SCHEMBL25876275 | 0.82 | PDE1A (0.36) | MAT2AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | MAT2A 686/4885PDE2A 1000/4885MEN1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.